Related Experiment Video

Updated: Mar 29, 2026

Monitoring Functionality and Morphology of Vasculature Recruited by Factors Secreted by Fast-growing Tumor-generating Cells
09:03

Monitoring Functionality and Morphology of Vasculature Recruited by Factors Secreted by Fast-growing Tumor-generating Cells

Published on: November 23, 2014

10.2K

Peptides to Target Tumor Vasculature and Lymphatics for Improved Anti-Angiogenesis Therapy

P R Sivashankari, M Prabaharan1

  • 1Department of Chemistry, Hindustan Institute of Technology and Science, No.1, Rajiv Gandhi Salai, Padur, Chennai 603 103, India. mprabaharan@yahoo.com.

Current Cancer Drug Targets
|December 4, 2015
PubMed

Insights

Peptides show promise as targeted ligands for anti-angiogenesis cancer therapy. These molecules selectively target tumor vasculature, improving treatment efficacy and minimizing side effects on healthy cells.

Area of Science:

  • Oncology
  • Biomedical Engineering
  • Drug Delivery

Background:

  • Cancer remains a leading cause of mortality globally.
  • Current cancer therapies lack specificity, harming healthy cells.
  • Targeted drug delivery systems offer improved cancer diagnosis and treatment.

Purpose of the Study:

  • To review recent advancements in peptide-based targeted drug delivery.
  • To focus on peptides as ligands for anti-angiogenesis therapy.
  • To highlight the potential of targeting tumor vasculature.

Main Methods:

  • Review of current scientific literature on targeted therapy and angiogenesis.
  • Analysis of peptide ligands for targeting blood and lymphatic vessels.
  • Evaluation of anti-angiogenesis strategies.

Main Results:

  • Disrupting tumor blood and lymphatic vessels is an effective cancer treatment strategy.
  • Peptides offer advantages as targeting ligands over other molecules.
  • Targeted agents can reach tumor cells specifically, reducing off-target effects.

Conclusions:

  • Peptides are effective ligands for targeted drug delivery in cancer therapy.
  • Targeting tumor vasculature with peptides enhances anti-angiogenesis treatment.
  • Peptide-based therapies hold significant potential for improved cancer outcomes.

More Related Videos

Intravital Microscopy of Tumor-associated Vasculature Using Advanced Dorsal Skinfold Window Chambers on Transgenic Fluorescent Mice08:52

Intravital Microscopy of Tumor-associated Vasculature Using Advanced Dorsal Skinfold Window Chambers on Transgenic Fluorescent Mice

Published on: January 19, 2018

14.8K
Screening and Identification of Small Peptides Targeting Fibroblast Growth Factor Receptor2 using a Phage Display Peptide Library07:32

Screening and Identification of Small Peptides Targeting Fibroblast Growth Factor Receptor2 using a Phage Display Peptide Library

Published on: September 30, 2019

8.4K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.8K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.2K
Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
7.6K
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
4.0K
The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
8.1K